Annovis completes Phase III data unblinding for buntanetap; topline expected June

Annovis Bio, Inc.

Unblinding of Phase III study of buntanetap in early Parkinson's disease completed.
Topline efficacy data expected in June 2024.
Delay due to PK measurement error resolved; repeated analysis showed correct 33% blank samples.
Company confident in data integrity and ready for evaluation with FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.